Thalidomide

沙利度胺

Report date: 2026/04/03 20:03:44
NME

Base Information

Drug NameThalidomide
Drug Alias Name沙利窦迈TalidomidaThalidomidum酞胺哌啶酮Talizer +[15] 
ClassificationSmall molecules > Heterocyclic drugsSmall molecules > Molecular Glue
Mechanisms of ActionInterleukin-2 inhibitorsInterleukin-6 inhibitorsFibroblast growth factor 2 inhibitors +[8] 
TargetsFibroblast growth factor 2Interferon gammaInterleukin-12 +[8] 
Therapy Area/IndicationsPlaque psoriasisSkin MelanomaAxial Spondyloarthritis +[89] 
Global Approved IndicationsErythema NodosumMultiple MyelomaLeprosy, Lepromatous
Approved Indications in ChinaMultiple MyelomaLeprosy, Lepromatous
Original Approved Country/TerritoryMainland China
Original Approved Date1982/01/01
Country/TerritoryCzechiaBulgariaUnited States +[27] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesCelgene Corp
China Registration ClassN/A

Develop Information

Active CompaniesChangzhou Pharmaceutical FactoryVicore PharmaNational Institute Of Blood And Marrow Transplant (Nibmt), Pakistan +[10] 
Inactive CompaniesAugusta UniversityNational Institutes Of Health Clinical Center (Cc)Wake Forest University +[31] 
Active IndicationsErythema NodosumGenetic Diseases, InbornHemoglobinopathies +[19] 
Inactive IndicationsPlaque psoriasisSkin MelanomaAxial Spondyloarthritis +[70] 

Other Information

ATC CodeL04AX02
Related LinksWikipediaDrugBankKEGG